A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Clin Cancer ResSep 1, 2026
Clinical ResearchOncology (Medical)GastroenterologyOpen access

Hong Jae Chon, Jeong Heo, Do Young Kim et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter, single-arm Phase Ib/IIa study evaluated the combination of fostroxacitabine bralpamide (fostrox) and lenvatinib in 21 patients with advanced hepatocellular carcinoma (HCC) who progressed on prior therapy. The study found an overall response rate of 24% and a median overall survival of 13.7 months, indicating promising efficacy and tolerability for this second-line treatment option.

Key findings

  • Overall response rate was 24% in the study population.
  • Median overall survival was 13.7 months.
  • Disease control rate reached 81% among participants.
  • No treatment-related liver function deterioration was observed.

Why it matters

The study highlights a potential second-line treatment option for advanced HCC patients who have limited choices after immunotherapy, emphasizing the need for effective therapies in this challenging population.

Source

PubMed · PMID 42262258Free full text on PubMed Central

Published in Clin Cancer Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.